Q-omics provides the consensus-scored FARSBP1 profile across patient tissues and cancer cell-line models. FARSBP1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FARSBP1 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, FARSBP1 RNA expression shows 6,305 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, COAD, and STAD as cancer lineages where FARSBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FARSBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FARSBP1 survival associations across molecular data types. FARSBP1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FARSBP1 RNA expression–survival associations across cancer types. High FARSBP1 expression shows unfavorable associations in ACC, THYM, UVM, CESC and LUSC, but favorable associations in COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FARSBP1 RNA expression.
This table summarizes FARSBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FARSBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FARSBP1 shows lower tumor expression in KIRP and higher tumor expression in COAD. The COAD box plot shows higher FARSBP1 RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p = .044).
This table shows molecular features associated with FARSBP1 in patient tissues and cancer cell lines. In patient samples, FARSBP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
